

Report

Isolation of a cDNA Representing the Fanconi Anemia Complementation Group E Gene

Johan P. de Winter,¹ France Léveillé,¹ Carola G. M. van Berkel,¹ Martin A. Rooimans,¹ Laura van der Weel,¹ Jurgen Steltenpool,¹ Ilja Demuth,³ Neil V. Morgan,⁴ Noa Alon,⁵ Lucine Bosnoyan-Collins,⁵ Jeff Lightfoot,⁵ Peter A. Leegwater,² Quinten Waisfisz,¹ Kenshi Komatsu,⁶ Fré Arwert,¹ Jan C. Pronk,¹ Christopher G. Mathew,⁴ Martin Digweed,³ Manuel Buchwald,⁵ and Hans Joenje¹

Departments of ¹Clinical Genetics and Human Genetics and ²Clinical Chemistry, Free University Medical Center, Amsterdam; ³Institute of Human Genetics, Charité-Campus Virchow-Klinikum, Humboldt University, Berlin; ⁴Division of Medical and Molecular Genetics, GKT School of Medicine, Guy's Hospital, London; ⁵Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, The University of Toronto, Toronto; and ⁶Department of Radiation Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima

Fanconi anemia (FA) is an autosomal recessive chromosomal instability syndrome with at least seven different complementation groups. Four FA genes (*FANCA*, *FANCC*, *FANCF*, and *FANCG*) have been identified, and two other FA genes (*FANCD* and *FANCE*) have been mapped. Here we report the identification, by complementation cloning, of the gene mutated in FA complementation group E (*FANCE*). *FANCE* has 10 exons and encodes a novel 536–amino acid protein with two potential nuclear localization signals.

Fanconi anemia (FA) is characterized by bone marrow failure, developmental abnormalities, cancer predisposition, and cellular hypersensitivity to DNA cross-linking agents such as mitomycin C (Auerbach et al. 1998 [MIM 227650]). Complementation analysis has indicated that mutations in at least seven different genes can cause FA (Joenje et al. 1997, 2000). Four FA genes have been identified: *FANCA* (Fanconi Anemia/Breast Cancer Consortium 1996; Lo ten Foe et al. 1996 [MIM 227650]), *FANCC* (Strathdee et al. 1992 [MIM 227645]), *FANCF* (de Winter et al. 2000 [MIM 603467]) and *FANCG* (de Winter et al. 1998 [MIM 602956]). Intriguingly, none of these genes has revealed any decisive clue toward a molecular function of the FA pathway, since they encode novel proteins that lack significant functional domains. The recently described homology between *FANCF* and the RNA-binding protein ROM (de Winter et al. 2000)

appeared to be nonsignificant, because mutations in the *FANCF* region homologous to ROM did not affect the function of *FANCF* (J. P. de Winter, unpublished data). Two other FA genes, *FANCD* and *FANCE*, have been mapped to chromosomes 3p25.3 (Whitney et al. 1995; Hejna et al. 2000 [MIM 227646]) and 6p21-22 (Waisfisz et al. 1999 [MIM 600901]), respectively.

Here we report the cloning of a cDNA representing *FANCE*, by complementation of the FA-E lymphoblastoid cell line EUFA410 (Waisfisz et al. 1999) with an episomal expression library (Strathdee et al. 1992). After selection for library uptake in hygromycin-containing medium (100 μ g/ml) and subsequent selection for resistance to mitomycin C (15 nM), 4 of the 12 cDNA clones that we recovered from the pool of complemented cells had identical inserts of \sim 2.5 kb. Secondary transfection of one of these cDNA clones (clone 10 [GenBank accession number AF265210]) into EUFA410 cells again complemented their MMC-hypersensitive phenotype (fig. 1a). The cDNA insert has a 1,611-nucleotide open reading frame encoding a 536–amino acid protein (fig. 1b). The predicted *FANCE* protein contains two potential nuclear localization signals but, like the other FA proteins, lacks any significant homology to other proteins.

The Stanford high-resolution TNG3 radiation-hybrid

Received August 16, 2000; accepted for publication September 8, 2000; electronically published September 19, 2000.

Address for correspondence and reprints: Dr. Hans Joenje, Department of Clinical Genetics and Human Genetics, Free University Medical Center, Van der Boerhorststraat 7, NL-1081 BT Amsterdam, The Netherlands. E-mail: H.Joenje.HumGen@med.vu.nl

© 2000 by The American Society of Human Genetics. All rights reserved. 0002-9297/2000/6705-0027\$02.00

panel was used to position *FANCE* between microsatellite markers *D6S439* and *D6S1645*, in agreement with the genetic map location of *FANCE* (Waisfisz et al. 1999). The *FANCE* cDNA appeared identical to a human genomic DNA sequence (clone 109F14 [Genbank accession number AL022721]; Tripodis et al. 2000) on chromosome 6p21.2-21.3. A comparison between this genomic DNA sequence and the *FANCE* cDNA revealed that the *FANCE* gene has 10 exons spanning ~15 kb of genomic sequence. *FANCE* appears to be located between the genes encoding the 60S ribosomal protein RPL10A (Csa-19) and a ZNF127-like protein, a region in which cDNA selection, exon trapping, and exon prediction programs failed to detect a gene (Tripodis et al. 2000).

Mutation screening of the *FANCE* gene revealed a homozygous C→T transition in exon 2 of EUFA410, which changes codon 141 into a stop codon (R141X; table 1). The parents were heterozygous for this mutation. In the FA-E reference cell line EUFA130 (Joenje et al. 1997), a homozygous C→T nonsense mutation was found in codon 119 (Q119X; table 1). The parents and unaffected brother were heterozygous for this mutation. A homozygous mutation IVS5-8G→A was detected in genomic DNA from FA-E cell line EUFA622 (Waisfisz et al. 1999), which creates an alternative splice-acceptor site (table 1). Sequence analysis of cDNA derived from EUFA622 indicated that

Table 1

Mutations in Three FA-E Patients

Patient	Ancestry	Mutation	Consequence for Protein
EUFA121	Turkey	355 C→T	Q119X
EUFA410	Bangladesh	421 C→T	R141X
EUFA622	Turkey	IVS5-8G→A ^a	R371_I372insLX


NOTE. Nucleotide numbering starts at the translation initiation site. All these patients are homozygous for the indicated mutations.

^a Mutation IVS5-8G→A (underlined) tttagctgtag ATC CTC creates an alternative splice-acceptor site that results in false splicing and insertion of six nucleotides from intron 5 (underlined), including an in-frame stop codon GGA CGG ctg tag ATC CTC.

this mutation results in false splicing and incorporation of six nucleotides from intron 5, including an in-frame stop codon. These findings confirmed the identity of the *FANCE* gene.

Our data show that *FANCE* encodes a novel protein with two nuclear localization signals, which strongly suggests that the pathway defective in FA patients has a nuclear function. Although recent evidence indicates that the FA pathway might be involved in cellular detoxification (Kruyt et al. 1998), transcriptional repression (Hoatlin et al. 1999), or STAT1 activation (Pang et al. 2000), the precise nature of this pathway remains to be elucidated.

Given that *FANCE* is localized in a region containing



b

```

1  MATPDAGLPGAEGVEPAPWAQLEAPARLLLQALQAGPEGARRGLGVLRALGSRGWEPFDW  60
61  GRLLLEALCREEPVVQGPDRLELKPLLLLRPRICQRNLSLLMAVRPSLPESGLLSVLQI  120
121 AQQDLAPDPDAWLRALGELLRRDLGVGTSMEGASPLSERCQRQLQSLCRGLGLGRRRLKS  180
181 PQAPDPEEEENRDSQQPGKRRKDSEEEAASPEGKRVPKRLRCWEEEEEEDHEKERPEHKSLE  240
241 SLADGGSASPIKDQPFVMAVKTGEDGSNLDDAKGLAESLELPKAIQDQLPRLQQLLKTLEE  300
301 GLEGLEDAAPPVELQLLHECSPSQMDLLCAQLQLPQLSDLGLLRRLCTWLLALS PDL SLSNA  360
361 TVLTRSFLGRILSLTSSASRLLTALTSFCAKYTPVCSALLDPVLQAPGTGPAQTELL  420
421 CCLVKMESLEPDAQVLM LGQILELPWKEETFLVLSLLERQVEMTPEKFSVLM EKLCCKG  480
481 LAATTSMAYAKLMLTVMTKYQANITETQRLGLAMALEPNTTFLRKS LKAALKHLGP  536
    
```

Figure 1 Complementation of MMC hypersensitivity in FA-E lymphoblastoid cell line EUFA410, and *FANCE* protein sequence. *a*, MMC hypersensitivity of FA-E cell line EUFA410 is corrected after transfection of *FANCE* cDNA clone 10. HSC93, wild type control. *b*, Amino acid sequence of the *FANCE* protein. Nuclear localization signals as predicted by PSORT II (Nakai and Horton, 1999) are shown in bold and underlined.

the HLA class I genes of the major histocompatibility complex (Waisfisz et al. 1999; Tripodis et al. 2000), group E patients are very unlikely to have an HLA-matched unaffected sibling donor for successful bone marrow transplantation. The cloning of *FANCE* now makes this group of patients prime candidates for gene-therapy trials aiming at genetic correction of their bone marrow failure (Liu et al. 1999).

Acknowledgments

We thank the families for participating, and we thank C. Altay, G. R. Evans, and W. Ebell for referring patients. Financial support was from the Dutch Cancer Society (VU-97-1565), the Fanconi Anemia Research Fund, Inc., the FA patient support organizations in Europe, the Commission of the European Union (contracts PL931562 and BMH4-98-3784), the Medical Research Council of Canada, and the National Institutes of Health (grant HL50131).

Electronic-Database Information

Accession numbers and URLs for data in this article are as follows:

GenBank, <http://www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html> (for human *FANCE* cDNA sequence [accession number AF265210] and genomic DNA clone 109F14 [accession number AL022721])
 Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for *FANCA* [MIM 227650], *FANCC* [MIM 227645], *FANCD* [MIM 227646], *FANCE* [MIM 600901], *FANCF* [MIM 603467], and *FANCG* [MIM 602956])

References

- Auerbach AD, Buchwald M, Joenje H (1998) Fanconi anemia. In: Vogelstein B, Kinzler KW (eds) *The genetic basis of human cancer*. McGraw-Hill, New York, pp 317–332
- de Winter JP, Waisfisz Q, Rooimans MA, van Berkel CG, Bosnoyan-Collins L, Alon N, Carreau M, Bender O, Demuth I, Schindler D, Pronk JC, Arwert F, Hoehn H, Digweed M, Buchwald M, Joenje H (1998) The Fanconi anemia group G gene *FANCG* is identical with *XRCC9*. *Nat Genet* 20: 281–283
- de Winter JP, Rooimans MA, van der Weel L, van Berkel CG, Alon N, Bosnoyan-Collins L, de Groot J, Zhi Y, Waisfisz Q, Pronk JC, Arwert F, Mathew CG, Scheper RJ, Hoatlin ME, Buchwald M, Joenje H (2000) The Fanconi anaemia gene *FANCF* encodes a novel protein with homology to ROM. *Nat Genet* 24:15–16
- Fanconi Anemia/Breast Cancer Consortium (1996) Positional cloning of Fanconi anemia group A gene. *Nat Genet* 14: 324–328
- Hejna JA, Timmers CD, Reifsteck C, Bruun DA, Lucas LW, Jakobs PM, Toth-Fejel S, Unsworth N, Clemens SL, Garcia DK, Naylor SL, Thayer MJ, Olson SB, Grompe M, Moses RE (2000) Localization of the Fanconi anemia complementation group D gene to a 200-kb region on chromosome 3p25.3. *Am J Hum Genet* 66:1540–1551
- Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht JD (1999) A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF. *Blood* 94: 3737–3747
- Joenje H, Levitus M, Waisfisz Q, D'Andrea A, Garcia-Higuera I, Pearson T, van Berkel CGM, Rooimans MA, Morgan N, Mathew CG, Arwert F (2000) Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A. *Am J Hum Genet* 67:759–762
- Joenje H, Oostra AB, Wijker M, di Summa FM, van Berkel CG, Rooimans MA, Ebell, van Weel M, Pronk JC, Buchwald M, Arwert F (1997) Evidence for at least eight Fanconi anemia genes. *Am J Hum Genet* 61:940–944
- Kruyt FAE, Hoshino T, Liu JM, Joseph P, Jaiswal AK, Yousoufian H (1998) Abnormal microsomal detoxification implicated in Fanconi anemia group C by interaction of the FAC protein with NADPH cytochrome P450 reductase. *Blood* 92:3050–3056
- Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, Leitman SF, Pensiero M, Young NS, Walsh CE (1999) Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (*FANCC*). *Hum Gene Ther* 10:2337–2346
- Lo ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, Lightfoot J, Carreau M, Callen DE, Savoia A, Cheng NC, Van Berkel CGM, Strunk MHP, Gille JJP, Pals G, Kruyt FAE, Pronk JC, Arwert F, Buchwald M, Joenje H (1996) Expression cloning of a cDNA for the major Fanconi anemia gene, *FAA*. *Nat Genet* 14:320–323
- Nakai K, Horton P (1999) PSORT: a program for detecting the sorting signals of proteins and predicting their subcellular localization. *Trends Biochem Sci* 24:34–35
- Pang Q, Fagerlie S, Christianson TA, Keeble W, Faulkner G, Diaz J, Rathbun RK, Bagby GC (2000) The Fanconi anemia protein *FANCC* binds to and facilitates the activation of *STAT1* by gamma interferon and hematopoietic growth factors. *Mol Cell Biol* 20:4724–4735
- Strathdee CA, Gavish H, Shannon WR, Buchwald M (1992) Cloning of cDNAs for Fanconi's anemia by functional complementation. *Nature* 356:763–767
- Tripodis N, Palmer S, Phillips S, Milne S, Beck S, Ragoussis J (2000) Construction of a high-resolution 2.5-Mb transcript map of the human 6p21.2–6p21.3 region immediately centromeric of the major histocompatibility complex. *Genome Res* 10:454–472
- Waisfisz Q, Saar K, Morgan NV, Altay C, Leegwater PA, de Winter JP, Komatsu K, Evans DGR, Wegner R-D, Reis A, Joenje H, Arwert F, Mathew CG, Pronk JC, Digweed M (1999) The Fanconi anemia group E gene, *FANCE*, maps to chromosome 6p. *Am J Hum Genet* 64:1400–1405
- Whitney M, Thayer M, Reifsteck C, Olson S, Smith L, Jacobs PM, Leach R, Naylor S, Joenje H, Grompe M (1995) Microcell mediated chromosome transfer maps the Fanconi anemia group D gene to chromosome 3p. *Nat Genet* 11: 341–343